シタデル塞栓デバイス研究
The purpose of this study is to gather safety and effectiveness data on Stryker Neurovascular's Next Generation Target Detachable Coil (hereafter referred to as the Citadel Embolization Device), when used with Target Detachable Coils, in the treatment of wide-neck intracranial aneurysms.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
In this study, use of the Citadel Embolization Device will be limited to a population of patients with unruptured or ruptured wide-neck aneurysms who meet all study eligibility criteria. The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
研究の種類
研究の種類
入学 (実際)
入学
段階
段階
- 適用できない
連絡先と場所
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90048
- Cedars-Sinai Medical Center
-
San Francisco、California、アメリカ、94143
- UCSF Medical Center
-
San Francisco、California、アメリカ、94114
- California Pacific Medical Center
-
Walnut Creek、California、アメリカ、94598
- John Muir Health
-
-
Colorado
-
Englewood、Colorado、アメリカ、80113
- RIA Neurovascular
-
-
Florida
-
Gainesville、Florida、アメリカ、32608
- University of Florida
-
Jacksonville、Florida、アメリカ、32207
- Baptist Health
-
Miami、Florida、アメリカ、33136
- University of Miami/Jackson Memorial
-
Tampa、Florida、アメリカ、33606
- Tampa General Hospital
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana Methodist
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66160
- Kansas University Medical Center
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40506
- University of Kentucky
-
Lexington、Kentucky、アメリカ、40503
- Baptist Health
-
-
Massachusetts
-
Worcester、Massachusetts、アメリカ、01605
- UMass Memorial Health
-
-
Michigan
-
Flint、Michigan、アメリカ、48532
- McLaren Health Center
-
Grand Rapids、Michigan、アメリカ、49503
- Spectrum Health
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110
- Washington University
-
-
New York
-
New York、New York、アメリカ、10467
- Montefiore Medical Center
-
New York、New York、アメリカ、10021
- Weill Cornell
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44195
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19107
- Thomas Jefferson University
-
Philadelphia、Pennsylvania、アメリカ、19104
- University of Pennsylvania Hospital
-
-
Washington
-
Seattle、Washington、アメリカ、98104
- University of Washington
-
-
West Virginia
-
Morgantown、West Virginia、アメリカ、26506
- West Virginia University Hospital
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age is ≥18 and ≤80 years
- Has a single, unruptured or ruptured target intracranial aneurysm that is suitable for endovascular treatment. Definition: For the purposes of this study, a ruptured intracranial aneurysm is defined as one with CT/MRI/LP evidence of subarachnoid hemorrhage attributed to the index aneurysm within the last 60 days.
- Aneurysm morphology is saccular
- Aneurysm size is between 6-12 mm
- Has a wide-neck, saccular aneurysm, either bifurcation or sidewall, with a dome to neck ratio <2 or neck ≥4 mm
- If the target intracranial aneurysm is classified as ruptured, patient must be neurologically stable with a Hunt & Hess Score of 1 or 2.
- Must be willing to comply with protocol required procedures and follow up
- Subject or LAR must be willing to sign and date an IRB approved written informed consent prior to initiation of any screening or study procedures
Exclusion Criteria:
- Target aneurysm has been previously treated
- Target aneurysm is in any extradural location, including the extradural cavernous segment
- Has vessel characteristics, tortuosity or morphology or unfavorable aneurysm morphology (e.g., determined from baseline or preprocedure imaging, or which may be evidenced by excessive resistance felt during the procedure) that would preclude safe endovascular access to the target aneurysm necessary for treatment with the study device
- Has significant intracranial atherosclerotic disease or stenosis determined from baseline or pre-procedure imaging
- If the target intracranial aneurysm is classified as ruptured, patient is neurologically unstable or has a Hunt & Hess Score of ≥ 3
- Has a history of intracranial vasospasm not responsive to medical therapy
- Has undergone coiling or stenting of a non-target intracranial aneurysm within 30 days prior to study treatment or has a non-target intracranial aneurysm that is expected to be treated within 12 months following the treatment of the target aneurysm
- Treatment with flow diverting stent implant is anticipated
- A planned, staged procedure is anticipated
- Has Moya-Moya disease, arteriovenous malformation(s), arteriovenous fistula(e), intracranial tumor(s), intracranial hematoma(s), any other intracranial vascular malformation, or any previous major intracranial surgery
- Has had a recent (within 90 days) ischemic stroke, TIA, or intracranial hemorrhage
- Has a baseline mRS score ≥2
- Has a known coagulopathy or is on chronic anticoagulant therapy
- Is pregnant or intends to become pregnant during the study or is breastfeeding
- Is concurrently involved in another study that could affect outcomes of IA treatment
- Has evidence of active cancer, terminal illness, high risk of embolic stroke, unstable atrial fibrillation, significant co-morbidities, major surgery ≤ 30 days pre-procedure, psychiatric disorders, substance abuse, or a life expectancy of less than 5 years
- Has a contraindication to angiography, radiographic contrast agents, or any medications that are typically used during the procedure, and any other contraindications listed in the Investigational DFU
- Has a confirmed allergy to platinum, tungsten, nickel (e.g. nitinol), or other elements used in the manufacturing of the investigational device
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
他の:Citadel Embolization Device
The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms. |
The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Primary Safety Endpoint is stroke-related neurologic death, or major ipsilateral or disabling stroke in the territory supplied by the treated artery
時間枠:12 months post-procedure
|
Occurring within 12 months post-procedure as adjudicated by an independent Clinical Events Committee (CEC)
|
12 months post-procedure
|
|
Primary Effectiveness Endpoint of this study is adequate aneurysm occlusion without retreatment or significant parent artery stenosis (>50% stenosis).
時間枠:12 months post-procedure
|
The determination of adequate aneurysm occlusion using Raymond-Roy classification will be made if either of the following criteria in the description are met: -100% occlusion (Raymond Class I) demonstrated by Digital Subtraction Angiography (DSA) measurement at 12 months (± 3 months) post-procedure, or -Stable Raymond class II demonstrated on 2 serial imaging measurements using Contrast-Enhanced Magnetic Resonance Angiography (CE-MRA) and/or DSA obtained a minimum of 6 months (± 1 month) apart. Post-procedure and 12-month imaging must be completed with DSA. |
12 months post-procedure
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Secondary Safety Endpoint of this study is any stroke event occurring through 12 months post-procedure, where a stroke event is defined as per what is noted in the description.
時間枠:12 months post-procedure
|
-Rapidly developing clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours with no apparent cause other than of vascular origin, including ischemic stroke and/or hemorrhagic stroke (i.e., intraparenchymal hemorrhage [IPH], subarachnoid hemorrhage [SAH], subdural hemorrhage [SDH], epidural hemorrhage [EDH]) accompanied with radiological evidence. |
12 months post-procedure
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Ansaar Rai, MD、West Virginia University
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- CDM10001448
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。